Preliminary data from a Phase 3 clinical trial, KEYNOTE-204, showed that Merck’s (NYSE:MRK)
Keytruda (pembrolizumab) statistically significantly improved
progression-free survival (PFS) in adults with relapsed/refractory
classical Hodgkin lymphoma (cHL) compared to Seattle Genetics’ (NASDAQ:SGEN) Adcetris (brentuximab vedotin), one of the primary endpoints.
The other primary endpoint, overall survival, has yet to be tested.
The data will be presented at a future medical conference and submitted to regulatory authorities.
KEYNOTE-204 is the confirmatory study for Keytruda for cHL, approved in the U.S. in March 2017 on an accelerated basis.
https://seekingalpha.com/news/3547387-mercks-keytruda-tops-seattle-genetics-adcetris-in-late-stage-lymphoma-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.